NCT00211198 - Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2001

Primary Completion Date

January 31, 2005

Study Completion Date

January 31, 2006

Conditions

Lymphoma, T-Cell, Cutaneous

Interventions

DRUG

ONTAK (denileukin difitox, DAB389IL-2)

Trial Locations (9)

University of Pittsburgh, Pittsburgh

Vanderbilt University, Nashville

Ohio State University, Columbus

University Hospitals of Cleveland, Cleveland

The University of Iowa, Iowa City

City of Hope National Medical Center, Duarte

Yale University School of Medicine, New Haven

New England Medical Center, Boston

The University of Texas MD Anderson Cancer Center, Houston